Q-omics provides the consensus-scored TTTY13 profile across patient tissues and cancer cell-line models. TTTY13 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TTTY13 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, TTTY13 RNA expression shows 3,306 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, COAD, and STAD as cancer lineages where TTTY13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTTY13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTTY13 survival associations across molecular data types. TTTY13 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTTY13 RNA expression–survival associations across cancer types. High TTTY13 expression shows unfavorable associations in UCEC, LAML, SARC, LIHC and SKCM, but favorable associations in MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for TTTY13 RNA expression.
This table summarizes TTTY13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TTTY13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTTY13 shows higher tumor expression in COAD. The COAD box plot shows higher TTTY13 RNA expression in tumor versus normal tissue (log2 FC = +0.141, t-test p = .047).
This table shows molecular features associated with TTTY13 in patient tissues and cancer cell lines. In patient samples, TTTY13 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
